| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
22,790,000 |
| Market
Cap: |
24.16(M) |
| Last
Volume: |
563,483 |
Avg
Vol: |
252,607 |
| 52
Week Range: |
$0.502 - $7 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Durect is a biopharmaceutical company developing therapies derived from its Epigenetic Regulator Program. Larsucosterol (also known as DUR-928), a chemical entity in clinical development, is the primary candidate in Co.'s Epigenetic Regulator Program. A bioavailable small molecule, larsucosterol has been shown in both in vitro and in vivo studies to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival. Co. is conducting a double-blind, placebo-controlled Phase 2b clinical trial called AHFIRM, in which Co. is evaluating larsucosterol's life saving potential in patients with severe alcohol-associated hepatitis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
482,093 |
| Total Buy Value |
$0 |
$0 |
$0 |
$288,249 |
| Total People Bought |
0 |
0 |
0 |
4 |
| Total Buy Transactions |
0 |
0 |
0 |
15 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Sussman Norman |
Chief Medical OfficerOfficer |
• – – |
2020-11-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
9,000 |
|
34% |
|
| Bleichroeder Lp |
10% Owner |
– – • |
2020-09-01 |
4 |
S |
$1.68 |
$420,000 |
I/I |
(250,000) |
26,414,656 |
|
-25% |
|
| Joice Judy R |
Sr. VP Operations & Corp QA |
• – – |
2020-06-03 |
4 |
S |
$2.45 |
$141,763 |
D/D |
(57,820) |
32,747 |
|
22% |
|
| Joice Judy R |
Sr. VP Operations & Corp QA |
• – – |
2020-06-03 |
4 |
OE |
$0.78 |
$45,100 |
D/D |
57,820 |
55,703 |
|
- |
|
| Bleichroeder Lp |
10% Owner |
– – • |
2020-05-26 |
4 |
S |
$2.50 |
$98,525 |
I/I |
(39,388) |
26,664,656 |
|
34% |
|
| Bleichroeder Lp |
10% Owner |
– – • |
2020-02-06 |
4 |
B |
$1.65 |
$123,623 |
I/I |
75,000 |
26,704,044 |
1.5 |
35% |
|
| Bleichroeder Lp |
10% Owner |
– – • |
2020-02-05 |
4 |
B |
$1.69 |
$126,777 |
I/I |
74,998 |
26,629,044 |
1.5 |
37% |
|
| Bleichroeder Lp |
10% Owner |
– – • |
2020-02-04 |
4 |
B |
$1.70 |
$131,510 |
I/I |
77,500 |
26,554,046 |
1.5 |
35% |
|
| Bleichroeder Lp |
10% Owner |
– – • |
2019-09-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
26,476,546 |
|
- |
|
| Arnhold & S. Bleichroeder Holdings, Inc. |
10% Owner |
– – • |
2019-09-01 |
4 |
D |
$0.00 |
$0 |
I/I |
(26,476,546) |
0 |
|
- |
|
| Arnhold & S. Bleichroeder Holdings, Inc. |
10% Owner |
– – • |
2019-06-20 |
4 |
B |
$0.52 |
$2,080,000 |
I/I |
4,000,000 |
26,476,546 |
1.5 |
- |
|
| Saxe Jon S |
Director |
– • – |
2019-06-10 |
4 |
B |
$0.54 |
$13,750 |
I/I |
25,000 |
150,000 |
2.1 |
- |
|
| Saxe Jon S |
Director |
– • – |
2019-05-24 |
4 |
B |
$0.63 |
$18,903 |
I/I |
30,000 |
125,000 |
2.1 |
- |
|
| Saxe Jon S |
Director |
– • – |
2019-05-13 |
4 |
B |
$0.70 |
$6,773 |
I/I |
9,600 |
95,000 |
2.1 |
- |
|
| Saxe Jon S |
Director |
– • – |
2019-05-13 |
4 |
B |
$0.68 |
$28,095 |
I/I |
40,400 |
85,400 |
2.1 |
- |
|
| Saxe Jon S |
Director |
– • – |
2019-03-13 |
4 |
B |
$0.82 |
$17,480 |
I/I |
21,300 |
41,300 |
2.1 |
- |
|
| Saxe Jon S |
Director |
– • – |
2019-03-13 |
4 |
B |
$0.82 |
$3,021 |
I/I |
3,700 |
45,000 |
2.1 |
- |
|
| Arenberg Michael |
Chief Financial Officer |
• – – |
2019-03-12 |
4 |
B |
$0.80 |
$7,990 |
D/D |
10,000 |
24,426 |
2.74 |
- |
|
| Brown James E |
President & CEO |
• • – |
2018-11-27 |
4 |
B |
$0.81 |
$8,116 |
I/I |
10,000 |
80,000 |
2.58 |
- |
|
| Blaschke Terrence F |
Director |
– • – |
2017-09-27 |
4 |
OE |
$0.82 |
$20,495 |
D/D |
25,000 |
28,000 |
|
- |
|
| Benito Simon X |
Director |
– • – |
2017-09-25 |
4 |
OE |
$0.82 |
$20,495 |
D/D |
25,000 |
85,000 |
|
- |
|
| Hoffmann Dave |
Director |
– • – |
2017-09-21 |
4 |
OE |
$0.82 |
$98,895 |
D/D |
95,000 |
120,000 |
|
- |
|
| Theeuwes Felix |
Chairman and CSO |
• • – |
2016-12-15 |
4 |
GD |
$0.00 |
$0 |
I/I |
64,500 |
3,331,814 |
|
- |
|
| Arnhold & S. Bleichroeder Holdings, Inc. |
10% Owner |
– – • |
2016-11-03 |
4 |
B |
$1.14 |
$110,298 |
I/I |
95,000 |
22,476,546 |
1.5 |
- |
|
| Arnhold & S. Bleichroeder Holdings, Inc. |
10% Owner |
– – • |
2016-09-26 |
4 |
B |
$1.10 |
$2,878,873 |
D/D |
2,500,000 |
22,381,546 |
2.45 |
- |
|
152 Records found
|
|
Page 2 of 7 |
|
|
0.07 (6.19%) 
